[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obsessive---compulsive-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obsessive---compulsive-disorder":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,50,79,104,133,159,188,213,246,268,297,321],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100639223","effect-of-emotion-focused-acceptance-and-commitment-therapy-on-obsessive-compulsive-disorder-symptom-severity-100639223",false,"NCT07622654","Effect of Emotion-Focused Acceptance and Commitment Therapy on Obsessive-Compulsive Disorder Symptom Severity","The Effect of Emotion-Focused Acceptance and Commitment Therapy on Obsessive-Compulsive Disorder Symptom Severity: A Randomized Controlled Trial","ACT-OCD","Inclusion Criteria:\n\n* Diagnosis of Obsessive-Compulsive Disorder according to DSM-5 criteria\n* Age between 18-65 years\n* Minimum literacy level\n* Willingness to participate and providing informed consent\n\nExclusion Criteria:\n\n* Age over 65 years\n* Diagnosis of alcohol or substance use disorder\n* Comorbid psychotic disorder or intellectual disability\n* Any change in psychiatric treatment (medication or psychotherapy) in the last 3 months\n* Comorbid psychiatric disorder that would impair group therapy compliance\n* History of cognitive impairment due to dementia, organic brain syndrome or other neurological\u002Forganic pathology","ALL","18 Years","65 Years",{"count":21,"type":22},36,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to investigate the effect of Emotion-Focused Acceptance and Commitment Therapy (ACT) group psychotherapy on obsessive-compulsive disorder (OCD) symptom severity. Participants with OCD will be randomly assigned to either an ACT-based group psychotherapy arm or a supportive group psychotherapy arm. Each arm consists of 10 to 12 weekly sessions of 2 hours. Symptom severity, psychological flexibility, emotional awareness, functioning and quality of life will be assessed before and after the intervention.",[28,29],"OCD","Obsessive - Compulsive Disorder",[31,32,33,34,28,35,36],"ACT","Acceptance and Commitment Therapy","Obsessive-Compulsive Disorder","Group Psychotherapy","Emotion-Focused Therapy","Psychological Flexibility","RECRUITING","2026-05-30",{"date":40,"type":41},"2026-06-03","ACTUAL",{"date":43,"type":41},"2025-10-01",{"date":45,"type":22},"2026-06-01",{"name":47,"class":48},"Mehmet Emrah Karadere","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":49},"100592405","phase-1-psilocybin-for-treatment-of-ocd-2-100592405","NCT06992999","Psilocybin for Treatment of OCD-2","Psilocybin for Treatment of Obsessive Compulsive Disorder","Inclusion Criteria:\n\n* Aged 18 years old, and older\n* Have OCD (DSM-5) based on diagnostic interview using the Structured Clinical Interview for DSM-5 Research Version (SCID).\n* At least moderate severity: Yale-Brown Obsessive-Compulsive Scale (YBOCS) score ≥16.\n* Failed at least one adequate trial of guideline concordant treatment.\n* Considered safe for independent living\n* Subjects must discontinue use of any of the following prescription or over the counter (OTC) products or nutritional supplements at least two weeks prior to initiating double-blind treatment:\n* Monoamine oxidase (MAOI), UGT1A10, and UGT1A9 inhibitors\n* Other active OCD treatments (cognitive behavioral therapy \\[CBT\\] or other psychotherapy; electrical or magnetic device treatments; pharmacological treatments such as antidepressant medications (e.g., SSRIs, SNRIs, MAOIs, TCAs, 5HT2 blockers, NERIs, etc.), lithium, antipsychotic drugs, 5-HT2 antagonists such as pimavanserin, and glutamatergic acting medications)\n\n  * Note that fluoxetine must be discontinued at least 6 weeks prior to initiating double-blind treatment.\n* 5HT2 agonists (e.g., efavirenz, lorcaserin), which may alter the response to psilocybin\n* Serotonin-acting dietary supplements (e.g., 5-hydroxy-tryptophan, St. John's wort) due to potential for interaction with psilocybin and increased safety risks\n\nExclusion Criteria:\n\n* Concurrent active substance use disorder, or a personal history of psychosis.\n* History of psychosis among first degree relatives as determined by the Family Interview for Genetic Studies (FIGS) 32\n* Medical illness based on physical examination and routine blood testing that may complicate cardiovascular safety or drug metabolism or excretion, such as uncontrolled hypertension, severe cardiac disease, or kidney or liver failure.\n* Unstable Chronic Obstructive Pulmonary Disease (COPD) or severe sleep apnea\n* Clinically significant renal or hepatic impairment, per clinical judgment of a study physician\n* EKG QTc ≥ 450 msec\n* Psychiatric comorbidity that may represent an acute risk to their own or other's safety.\n* Subjects cannot require any sedative, narcotic, or neuroleptic medications on a regular basis. Any of these medications they have taken should have been stopped long enough in the past to allow for their elimination and safe withdrawal prior to starting administration of the study drug. The specific time required will be dependent on the medication the patient was previously receiving.\n* Women who are pregnant, breastfeeding, or unwilling\u002Funable to practice medically acceptable highly effective birth control (double barrier, oral and injectable pharmacological contraceptives) during the study.\n* Suicidal behavior within the 12 months prior to enrollment, or significant risk of suicide as determined by the CSSRS items 4 (suicidal ideation with intent) and 5 (suicidal ideation with intent and plan) during screening or baseline assessment.\n* Any condition for which MRI is contraindicated, at the discretion of a study investigator or the MRI technician, including: Pacemakers and defibrillators; artificial heart valves which are not MRI safe; any metal in head, spinal cord, eyes or chest; any electrical devices such as cochlear implants, nerve stimulators, deep brain stimulators, gastric pacemaker, or insulin or pain pumps; aneurysm clips; ferrous (i.e. non titanium alloy) implants in any part of the body.\n* Use within the week prior to screening of drugs of abuse as listed in the current US DOJ DEA Drugs of Abuse Resource Guide, including:\n* Cannabinoids (marijuana, synthetic cannabinoids)\n* Simulants (amphetamine, cocaine, methamphetamine, methylphenidate, modafinil)\n* Opioids (natural and synthetic),\n* Sedatives (benzodiazepines, barbiturates, GHB, zolpidem, zaleplon, zopiclone)\n* Hallucinogens (DMT, ibogaine, LSD, MDMA, psilocybin, psilocin, PSP)",{"count":58,"type":22},20,[60,61],"PHASE1","PHASE2","Previous research indicates that psilocybin, a drug that changes activity in brain areas believed to be involved in obsessive-compulsive disorder (OCD), might improve treatment for, and improve lives of, people diagnosed with OCD. The investigators propose to study 20 patients with symptomatic OCD who are not taking mind altering medications or street drugs, to participate in a 12 week study. Participants will be assigned (by luck of the draw) to take low or high dose psilocybin in four dosing sessions separated by 3 weeks. Measurements for the severity of OCD, ability to function, perception of quality of life, safety and tolerability will be measured at baseline prior to drug administration, during the dosing periods, and at the end of study. Other measurements will include brain imaging via fMRI and brain tracing via electroencephalogram (EEG). The investigators believe that during medically supervised dosing sessions, both doses of psilocybin will be safe and well tolerated, and will reduce OCD symptoms. Because psilocybin is a potent drug and especially at the higher dose may induce altered states of consciousness, a thoughtfully implemented procedure for participant safety is in place. Information will be obtained to explore the effects of altered states of consciousness in the outcome of treatment and to find the mechanism of benefit.",[29],[65,28,66,67,68],"obsessive compulsive disorder","psilocybin","psychedelic","psychedelic experiences","NOT_YET_RECRUITING","2026-05-11",{"date":72,"type":41},"2026-05-12",{"date":74,"type":22},"2026-09-08",{"date":76,"type":22},"2028-12",{"name":78,"class":48},"Francisco A Moreno",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":49},"100636118","electrophysiological-biomarkers-and-treatment-response-to-accelerated-transcranial-magnetic-stimulation-in-patients-with-obsessive-compulsive-disorder-100636118","NCT07561528","Electrophysiological Biomarkers and Treatment Response to Accelerated Transcranial Magnetic Stimulation in Patients With Obsessive-Compulsive Disorder","Investigation of the Relationship Between Electrophysiological Biomarkers and Treatment Response in Patients Diagnosed With Obsessive-Compulsive Disorder Undergoing Transcranial Magnetic Stimulation Therapy","TMS-OCD-EEG","Inclusion Criteria:\n\n* Being between 18 and 65 years of age.\n* Being diagnosed with Obsessive-Compulsive Disorder (OCD) according to DSM-5 criteria.\n* Non-responsiveness to at least one Selective Serotonin Reuptake Inhibitor (SSRI) treatment at an adequate dose and duration.\n* Having a Y-BOCS score of ≥20 following the initial evaluation.\n* No change in the current medications within the last 2 months and a commitment to maintaining stable doses throughout the study.\n* Providing informed consent and having no contraindications for TMS.\n\nExclusion Criteria:\n\n* Severe neurological disorders or neurodegenerative diseases.\n* Any condition associated with increased seizure risk\n* History of cochlear implants, metal implants in the head and neck area, cardiac pacemakers, deep brain stimulation, or vagus nerve stimulation.\n* History of neurosurgical intervention.\n* General contraindications for Transcranial Magnetic Stimulation therapy.",{"count":88,"type":22},30,[25],"Purpose:\n\nThis study aims to evaluate the effectiveness of an accelerated intermittent Theta Burst Stimulation (iTBS) protocol-a non-invasive brain stimulation technique-targeted at the dorsomedial prefrontal cortex (dmPFC) and anterior cingulate cortex (ACC) in patients with treatment-resistant Obsessive-Compulsive Disorder (OCD). Additionally, the study seeks to identify electrophysiological biomarkers (such as EEG microstates and heart rate variability) that may predict which patients are most likely to benefit from the treatment.\n\nMethodology:\n\nThe study will include 30 patients aged 18-65 diagnosed with OCD according to DSM-5 criteria who have not responded sufficiently to standard treatments. Participants will undergo an intensive 7-day treatment program consisting of 4 iTBS sessions per day (totaling 28 sessions). Clinical symptoms will be assessed before and after the treatment using standardized scales, including the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), Hamilton Depression Rating Scale (HAM-D), and Hamilton Anxiety Rating Scale (HAM-A). Resting-state EEG measurements and heart rate data will be recorded during and after the sessions to analyze physiological changes.\n\nGoal:\n\nThe findings are expected to contribute to the development of personalized neuromodulation protocols and help identify predictors of treatment response for OCD patients.",[29,92,93,94],"Transcranial Magnetic Stimilation","Intermittent Theta Burst Stimulation","EEG","2026-05-07",{"date":97,"type":41},"2026-05-08",{"date":99,"type":41},"2026-01-01",{"date":101,"type":22},"2027-04-01",{"name":103,"class":48},"Istanbul University - Cerrahpasa",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":111,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":115,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":49},"100629879","neural-mechanisms-of-the-sensorymotor-circuit-in-sensory-phenomena-in-ocd-100629879","NCT07480408","Neural Mechanisms of the Sensorymotor Circuit in Sensory Phenomena in OCD","Neural Mechanisms of the Insula-Supplementary Motor Area Circuit in Sensory Phenomena in Obsessive-Compulsive Disorder","Inclusion Criteria:\n\nOCD with abnormal sensory phenomena\n\n1. Meet the diagnostic criteria for Obsessive-Compulsive Disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.\n2. Aged 18-55 years.\n3. Score ≥16 on the Yale-Brown Obsessive Compulsive Scale, indicating moderate to severe symptoms.\n4. Score \\>6 on the Sensory Phenomena Scale (SPS), indicating moderate to severe sensory phenomena.\n5. Right-handed.\n6. Either medication-free or on stable medication for at least 8 weeks.\n\nOCD without abnormal sensory phenomena\n\n1. Meet the diagnostic criteria for Obsessive-Compulsive Disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.\n2. Aged 18-55 years.\n3. Score ≥16 on the Yale-Brown Obsessive Compulsive Scale.\n4. Score ≤6 on the Sensory Phenomena Scale (SPS).\n5. Right-handed.\n6. Either medication-free or on stable medication for at least 8 weeks.\n\nExclusion criteria\n\n1. Meeting diagnostic criteria in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition for psychiatric disorders other than OCD or obsessive-compulsive personality disorder.\n2. OCD symptoms so severe that required assessments cannot be completed.\n3. Presence of severe suicidal ideation or high suicide risk.\n4. Pregnant women or women planning pregnancy in the near future.\n5. History of epilepsy or any medical condition that may induce seizures or intracranial hypertension.\n6. Contraindications to MRI, such as metallic implants.\n7. Clinically significant medical illnesses or abnormal laboratory findings.\n8. Inability to complete study procedures due to severe symptoms, low cognitive functioning, or poor cooperation.\n\nHealthy Controls Inclusion criteria\n\n1. No current or past psychiatric disorders meeting diagnostic criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.\n2. Aged 18-55 years.\n3. Right-handed. Exclusion criteria\n\n1\\. Pregnant women or women planning pregnancy in the near future. 2. History of epilepsy or any medical condition that may induce seizures or intracranial hypertension.\n\n3\\. Presence of severe suicidal ideation or high suicide risk. 4. Contraindications to MRI, such as metallic implants. 5. Clinically significant medical illnesses or abnormal laboratory findings. 6. Inability to complete study procedures due to severe symptoms, low cognitive functioning, or poor cooperation.",true,"55 Years",{"count":114,"type":22},120,[25],"The goal of this clinical study is to investigate the neural mechanisms of abnormal sensory phenomena in patients with Obsessive-Compulsive Disorder and to evaluate whether modulation of the insula-supplementary motor area circuit can improve these symptoms. The study will include adult patients with OCD (with or without sensory phenomena) and healthy volunteers.\n\nThe main questions it aims to answer are:\n\n* Do patients with OCD show abnormal activity in the insula-SMA circuit compared with healthy controls?\n* Is this abnormality associated with the presence and severity of abnormal sensory phenomena?\n* Can low-frequency rTMS targeting the Supplementary Motor Area improve sensory phenomena and obsessive-compulsive symptoms? Researchers will compare an on-line rTMS group (viewing body-focused videos during stimulation) with an off-line rTMS group (resting during stimulation) to evaluate whether task engagement enhances treatment effects.\n\nParticipants will:\n\n* Complete clinical assessments and behavioral tasks.\n* Undergo EEG and fMRI assessments.\n* Receive low-frequency rTMS targeting the Supplementary Motor Area.\n* Repeat assessments after the intervention.",[29],[119,120,121,122,123],"obsessive-compulsive disorder","sensory phenomena","supplementary motor area","insula","neuromodulation","2026-03-18",{"date":126,"type":41},"2026-03-20",{"date":128,"type":22},"2026-05-01",{"date":130,"type":22},"2028-12-31",{"name":132,"class":48},"Shanghai Mental Health Center",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":23,"phases":144,"briefSummary":145,"conditions":146,"keywords":147,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":158},"100625966","tdcs-and-symptom-provocation-in-treatment-resistant-ocd-100625966","NCT07429500","tDCS and Symptom Provocation in Treatment-Resistant OCD","Transcranial Direct Current Stimulation Associated With Symptom Provocation in the Management of Patients With Treatment-Resistant Obsessive-Compulsive Disorder.","PPS-TDCSTOC","Inclusion Criteria:\n\n* Diagnosis of Obsessive-Compulsive Disorder (OCD) according to DSM-5, with a duration ≥ 2 years.\n* Good insight, defined as a BABS score ≤ 18.\n* Chronic OCD, with either a Y-BOCS total score \\> 20 or a subscale score \\> 15.\n* Treatment-resistant OCD, defined as:\n\n  * failure of ≥ two adequate trials of SSRIs, or\n  * failure of one SSRI plus augmentation with an atypical antipsychotic,\n* and\u002For insufficient response after ≥ one year of cognitive-behavioural therapy.\n* Stable pharmacological treatment (fixed antidepressant dose) for at least 12 weeks prior to inclusion, with no significant improvement during this period.\n* Age 18 to 70 years.\n* Ability to provide informed written consent.\n* Affiliation with the French social security system.\n\nExclusion Criteria:\n\n* Women of childbearing potential without effective contraception, or those unwilling to maintain abstinence or contraception.\n* Pregnancy or breastfeeding.\n* Compulsory psychiatric hospitalisation.\n* Legal guardianship or curatorship.\n* Current DSM-5 Axis I disorder other than OCD (schizophrenia spectrum, bipolar disorder, substance use).\n* Current major depressive episode (MADRS \\> 21).\n* Suicide risk (MADRS item 10 \\> 3).\n* Dermatological lesions at electrode placement sites.\n* History of traumatic brain injury.\n* Presence of intracranial metal, pacemaker, or epilepsy.\n* Emergency situations or inability to provide informed consent.","70 Years",{"count":143,"type":22},178,[25],"The goal of this clinical trial is to learn if symptom provocation before transcranial Direct Current Stimulation (tDCS) in Obsessive-Compulsive Disorder (OCD) patients. The main question it aims to answer is:\n\nCan symptom-provocation before tDCS improve therapeutic response in OCD patients ?\n\nResearchers will compare the clinical outcomes of OCD patients having received, in one arm, tDCS and, in the other arm, patients having received tDCS preceded by symptom provocation to see if therapeutic response and various other clinical variables differ.",[29],[148],"tDCS","2026-02-17",{"date":151,"type":41},"2026-02-24",{"date":153,"type":22},"2026-04-01",{"date":155,"type":22},"2029-10-15",{"name":157,"class":48},"Centre Hospitalier Henri Laborit",6,{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":111,"sex":17,"minAge":18,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":169,"phases":4,"briefSummary":170,"conditions":171,"keywords":176,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":4},"100623347","assessments-of-obsessive-compulsive-symptoms-in-patients-with-substances-use-disorder-100623347","NCT07395453","Assessments of Obsessive-compulsive Symptoms in Patients With Substances Use Disorder","Assessments of Obsessive-compulsive Symptoms in Patients With Substances Use Disorder and Its Correlates","Inclusion Criteria:\n\n--Adults aged 18-50 years.\n\n* Willing and able to provide informed consent and participate in the study assessments.\n* For the case group: patients with a diagnosed substance use disorder (single or polysubstance) attending the inpatient or outpatient addiction management unit at the Neuropsychiatry Department, Assiut University Hospital.\n* For the control group: relatives, friends, or hospital workers without substance use disorder, recruited through invitation or advertisement.\n\nExclusion Criteria:\n\n* Severe psychiatric comorbidities such as schizophrenia, major depressive disorder, bipolar disorder, or anorexia nervosa.\n* Current intoxication or acute withdrawal state from substances.\n* Severe medical conditions including end-stage renal disease, metastatic cancer, severe heart failure, or chronic obstructive pulmonary disease.\n* Severe cognitive impairment","50 Years",{"count":168,"type":22},102,"OBSERVATIONAL","This observational, cross-sectional case-control study evaluates obsessive-compulsive symptoms among adults with substance use disorder compared with a demographically similar control group without substance use disorder. Patients aged 18-50 years attending the addiction management inpatient and outpatient services at Assiut University Hospital, and healthy controls recruited from relatives, friends, and hospital staff, will complete structured clinical interviews, the Yale-Brown Obsessive-Compulsive Scale, and other standardized scales for psychiatric symptoms, cognition, and quality of life. The main objective is to estimate the prevalence and severity of obsessive-compulsive symptoms in substance use disorder and examine their associations with sociodemographic and clinical factors, addiction severity, and quality of life in the recovery stage.",[29,172,173,174,175],"Obsessive Compulsive Disorder (OCD)","Obsessive Compulsive Behavior","Substance Abuse Disorder","Substance Use",[177,178],"obsessive-compulsive symptoms","substances use disorder","2026-02-01",{"date":181,"type":41},"2026-02-09",{"date":183,"type":22},"2026-03",{"date":185,"type":22},"2027-04",{"name":187,"class":48},"Assiut University",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":23,"phases":197,"briefSummary":198,"conditions":199,"keywords":200,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":4},"100611347","feasibility-and-efficacy-trial-of-a-culturally-adapted-guided-self-help-cbt-manual-for-ocd-100611347","NCT07239401","Feasibility and Efficacy Trial of a Culturally Adapted Guided Self-Help CBT Manual for OCD","Feasibility and Efficacy Trial of a Culturally Adapted Guided Self-Help CBT Manual for Obsessive-Compulsive Disorder: A Randomised Controlled Study From Pakistan","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Clinical diagnosis of OCD (with or without comorbid depression)\n* Minimum 5 years of formal education\n* Residing within commuting distance of the participating sites\n* Ability to read and write Urdu\n* Provision of informed written consent\n\nExclusion Criteria:\n\n* Current substance use or dependence (diagnosed)\n* Significant cognitive impairment (e.g., dementia or intellectual disability)\n* OCD with active psychosis",{"count":196,"type":22},108,[25],"This randomised controlled trial (RCT) aims to assess the feasibility, acceptability, and preliminary efficacy of a culturally adapted, guided self-help cognitive behaviour therapy (CBT) manual specifically designed for individuals with OCD in Pakistan.",[29],[28,201,202,203],"Obsessive compulsive disorder","Guided self-help","CBT","2025-11-15",{"date":206,"type":41},"2025-11-20",{"date":208,"type":22},"2025-11",{"date":210,"type":22},"2026-02",{"name":212,"class":48},"Pakistan Association of Cognitive Therapists",{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":23,"phases":222,"briefSummary":223,"conditions":224,"keywords":225,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":49},"100604201","transcranial-magnetic-stimulation-and-psychotherapy-for-treating-obsessive-compulsive-disorder-100604201","NCT07146438","Transcranial Magnetic Stimulation and Psychotherapy for Treating Obsessive-Compulsive Disorder","Precision Medicine for OCD - Biobehavioral Tracking of Transcranial Magnetic Stimulation (TMS) With Exposure and Response Prevention (ERP) for Refractory OCD","Inclusion Criteria:\n\n* Diagnosis of Obsessive-Compulsive Disorder (OCD) as determined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnostic criteria.\n* Live in Southern California and be willing to attend in-person to receive repetitive Transcranial Magnetic Stimulation (rTMS) 5 times per week for 6 weeks.\n* Have completed a prior course of Exposure and Response Prevention (ERP) therapy (at least ten sessions)\n* Currently take or have previously tried Serotonin Reuptake Inhibitor (SRI) medication for OCD\n* Willing to maintain psychotropic medication levels throughout the 16 weeks of the study\n\nExclusion Criteria:\n\n* Primary psychiatric diagnosis other than OCD\n* Active substance use disorder\n* Active suicidality\n* Active psychosis\n* History of seizures\n* Severe neurological impairment\n* Pregnant or planning to become pregnant\n* Received a prior rTMS course",{"count":221,"type":22},48,[25],"This study will test how people with OCD respond to a type of noninvasive brain stimulation, repetitive Transcranial Magnetic Stimulation (rTMS), when it is combined with psychotherapy. Participants will either engage in Exposure and Response Prevention (ERP) Therapy or supportive therapy (ST) while receiving rTMS. Biobehavioral data from wearable devices and smartphones will be collected to better predict treatment responses. Participants will also undergo repeat resting state functional Magnetic Resonance Imaging (rsfMRI) in order to assess neural predictors and mechanisms of treatment response.",[29],[226,227,28,228,33,229,230,231,232,233,234,235,236],"TMS","Transcranial Magnetic Stimulation","Obsessive Compulsive Disorder","rTMS","repetitive Transcranial Magnetic Stimulation","psychotherapy","ERP","Magventure","Mental Disorders","Inhibitory Learning","Exposure and Response Prevention","2025-10-23",{"date":239,"type":41},"2025-10-27",{"date":241,"type":22},"2025-11-10",{"date":243,"type":22},"2028-08",{"name":245,"class":48},"Adam Frank",{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":252,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":254,"enrollmentInfo":255,"targetDuration":4,"studyType":23,"phases":256,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":49},"100608210","accelerated-rtms-therapeutic-approach-for-refractory-obsessive-compulsive-disorder-100608210","NCT07198594","Accelerated rTMS Therapeutic Approach for Refractory Obsessive-Compulsive Disorder","A Study on the Efficacy and Safety of Accelerated Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder and Its Underlying Neurological Mechanisms","OCDTMS-IFC","Inclusion Criteria:\n\n* Volunteer subjects with Obsessive Compulsive Disorders (OCD) according to the Diagnostic and Statistical Manual of Mental Disorders (DSM V) criteria\n* without associated tics (\"Gilles de la Tourette\" Syndrome)\n* Age 18-60 years, right-handed\n* Disease severity: Yale-Brown Obsessive Compulsive Scale score ≥16 for OCD patients\n* Medication stable for at least 4 weeks\n* Resistant patients to standard treatments: partial but insufficient response (reduction of Y-BOCS score \\\u003C 35%) or lack of response to previous well conducted treatment including: optimal tolerated dose and adequate duration (\\> 12 weeks) of at least 2 Serotonin Reuptake Inhibitors (selective serotonin reuptake inhibitors, clomipramine), or 1 Serotonin Reuptake Inhibitors + 1 augmentation strategy (adjunction of an antipsychotic - such as risperidone or olanzapine or aripiprazole - or lithium or buspirone)\n* No systematic rTMS therapy in the past six months;\n* Signature of informed consent form;\n* Normal vision or corrected vision;\n* Capacity to complete protocol-specified tests.\n\nExclusion Criteria:\n\n* Abnormal cognitive status (assessed using MoCA with score \\\u003C24);\n* Other primary diagnosis than OCD (comorbid mild depression is tolerated)\n* Comorbid diagnosis of schizophrenia\u002F psychotic disorder, bipolar disorder, substance abuse or dependance3)\n* Significant self-harm intent or severe suicidal tendencies within the past year;\n* Irreversible visual or auditory impairment preventing completion of scales or related assessments;\n* Presence of metallic implants, such as pacemakers or stents;\n* Any current or potential medical, psychological, social, or geographical factors compromising patient safety or study participation;\n* Poor compliance;\n* Claustrophobia;\n* History of epilepsy or familial epilepsy\n* Pregnant or lactating women (women of childbearing potential must obtain a negative pregnancy test result prior to study commencement and employ medically approved contraceptive measures);\n* Deterioration or failure of vital organ function (cardiac, pulmonary, hepatic, renal, etc.); or unstable vital signs;\n* Conditions unsuitable for this stimulation site, such as increased intracranial pressure, elevated intraocular pressure, or glaucoma\n* History of or concomitant neurological disorders: cerebrovascular disease, central nervous system infections, Creutzfeldt-Jakob disease, Huntington's disease and Parkinson's disease, Lewy body dementia, traumatic brain injury dementia, other physical\u002Fchemical factors (drugs, alcohol, CO, etc.), significant somatic diseases (hepatic encephalopathy, pulmonary encephalopathy, etc.), intracranial space-occupying lesions (subdural haematoma, brain tumours), endocrine system disorders (thyroid disease, parathyroid disease), and dementia caused by vitamin deficiency or any other cause","60 Years",{"count":58,"type":22},[25],"The goal of this clinical trial is to learn if individualized accelerated repetitive transcranial magnetic stimulation (rTMS) targeting the inferior frontal cortex combined with symptom provocation works to treat obsessive-compulsive disorders (OCD) in adults. It will also learn about the safety of rTMS over right IFC. The main questions it aims to answer are:\n\n* Does rTMS using a new individualized IFC target relieve participants' OCD symptoms?\n* What medical problems do participants have when taking rTMS?\n\nParticipants will:\n\n* Take rTMS six times per day for 5 consecutive days\n* Visit the clinic once at baseline, the day and four weeks after treatment for checkups and tests",[172,29],"2025-09-21",{"date":261,"type":41},"2025-09-30",{"date":263,"type":41},"2025-07-03",{"date":265,"type":22},"2027-12-31",{"name":267,"class":48},"Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University",{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":274,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":276,"targetDuration":4,"studyType":23,"phases":278,"briefSummary":279,"conditions":280,"keywords":281,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":49},"100603353","accelerated-rtms-in-hospitalized-patients-with-ocd-a-feasibility-and-mechanistic-study-100603353","NCT07135414","Accelerated rTMS in Hospitalized Patients With OCD: a Feasibility and Mechanistic Study","Accelerated Repetitive Transcranial Magnetic Stimulation in Hospitalized Patients With Obsessive-Compulsive Disorder: a Feasibility and Mechanistic RCT","arTMS-OCD","Inclusion Criteria:\n\n* Age between 18 and 65\n* Hospitalization for Obsessive-Compulsive Disorder (OCD)\n* Participation in Exposure and Response Prevention Therapy\n* Significant OCD, as measured by a Y-BOCS score of 20 or higher (moderate to severe OCD symptoms)\n\nExclusion Criteria:\n\n* Acute suicidality: Individuals presenting with current suicidal ideation or behavior are excluded to ensure participant safety.\n* Psychotic disorder: patients with active psychotic disorders are excluded due to the complexity of their condition and potential interactions with the study protocol.\n* Current substance use disorder: active substance use disorders are exclusionary to prevent confounding effects on study outcomes.\n* Deep Brain Stimulation (DBS) for OCD: participants with an implanted DBS device for OCD are excluded due to potential interference with the study's interventions and safety concerns.",{"count":277,"type":22},60,[25],"This study investigates a new treatment approach for Obsessive-Compulsive Disorder (OCD), a condition characterized by unwanted repetitive thoughts and behaviors. The goal is to determine whether combining specialized inpatient care with repetitive Transcranial Magnetic Stimulation (rTMS) is feasible, well-tolerated, and effective. rTMS is a non-invasive procedure that uses magnetic pulses to stimulate specific areas of the brain. In this study, two types of rTMS will be tested: deep TMS (dTMS) and intermittent theta burst stimulation (iTBS). Both treatments will be administered using an accelerated protocol, involving multiple sessions per day over a two-week period.\n\nPatients will be randomly assigned to one of three groups: two groups will receive either dTMS or iTBS combined with Exposure and Response Prevention (ERP), a recognized psychotherapy for OCD; the third group will receive only ERP without rTMS.\n\nParticipant Requirements next to treatment:\n\nQuestionnaires: Patients will complete surveys before the treatment period, immediately after the treatment period, and four weeks post-treatment.\n\nMRI \\& EEG: Patients will undergo brain imaging (MRI) and brain wave (EEG) recordings before and after the treatment period.\n\nAdverse Effects Diary: Patients will maintain a daily log of any side effects experienced during the treatment period.\n\nThe study aims to assess the feasibility, safety, and effectiveness of this combined treatment approach and to examine its effects on underlying brain processes related to clinical outcomes.",[29],[28,226,282,283,228,227,284,285,286,287],"deep TMS","iTBS","OCD-TMS","Hospitalized","Hospitalised","dTMS","2025-08-18",{"date":290,"type":41},"2025-08-22",{"date":292,"type":41},"2025-05-25",{"date":294,"type":22},"2030-12-31",{"name":296,"class":48},"University Hospital, Ghent",{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":111,"sex":17,"minAge":304,"maxAge":305,"enrollmentInfo":306,"targetDuration":4,"studyType":23,"phases":308,"briefSummary":309,"conditions":310,"keywords":311,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":320,"locationsCount":49},"100588522","effect-of-a-family-based-cbt-self-help-intervention-for-adolescents-with-ocd-100588522","NCT06942494","Effect of a Family-Based CBT Self-Help Intervention for Adolescents With OCD","Effect of a Family-Based Cognitive Behavioral Therapy Self-Help Intervention for Adolescents With Obsessive-Compulsive Disorder：A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age between 10 and 17 years\n2. Satisfied with the diagnostic criteria for OCD in DSM-5\n3. 16≤CY-BOCS score ≤23\n4. Taking medication stably for 6 weeks\n5. Education level ⩾6 years\n6. At least one parent can accompany the patients throughout the entire intervention process\n7. The patient and the participating parent have sufficient reading and writing skills to complete the treatment intervention\n8. The patient and the participating parent have adequate auditory and visual abilities skills to complete the necessary examinations for the study\n\n(7) Right-handed (this criterion is for fMRI subjects only) (8) Subjects and their guardians understood the study and signed informed consent.\n\nExclusion Criteria:\n\n1. Obsessive-compulsive symptoms were too severe to participate in the experiment(CY-BOCS score ≥24)\n2. High risk of suicide\n3. Comorbid brain organic diseases, severe somatic diseases, learning disabilities, autism spectrum disorders, schizophrenia spectrum and other psychotic disorders, bipolar disorder, severe eating disorders, or substance abuse\n4. Completed a Cognitive Behavioral Therapy (CBT) course for OCD within the past 12 months.\n5. An IQ lower than 80\n6. Currently undergoing other psychological\u002Fphysical treatments\n7. Uncooperative or unable to complete treatment\n8. With metal implants in the body, such as pacemakers, intracranial silver clips, metal dentures, arterial stents, arterial clips, joint metal fixation, or other metal implants, etc. (this criterion is for fMRI subjects only)","10 Years","17 Years",{"count":307,"type":22},88,[25],"The goal of this clinical trial is to learn if self-help book can be used to treat obsessive-compulsive disorder (OCD) in adolescents aged 10 to 17. The main questions it aims to answer are:\n\nCan adolescents and their parents effectively reduce the severity of the obsessive-compulsive symptoms in adolescents who are already stably taking medications through self-help books? What are the characteristics of adolescents who are best suited to use self-help intervention book to treat obsessive-compulsive symptoms?\n\nResearchers will compare the use of a self-help books plus medication with medication alone to see if the combination of the self-help intervention and drug treatment can improve the obsessive-compulsive symptoms of adolescents more effectively.\n\nParticipants will:\n\n* Read one chapter of a self-help book and complete the corresponding exercise each week for 12 weeks\n* Visit the clinic before and after intervention for checkups and tests",[29],[29,312,313],"Adolescents","Bibliotherapy","2025-07-27",{"date":316,"type":41},"2025-07-30",{"date":318,"type":41},"2025-04-30",{"date":265,"type":22},{"name":132,"class":48},{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":328,"targetDuration":4,"studyType":23,"phases":329,"briefSummary":330,"conditions":331,"keywords":332,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":344},"100595368","efficacy-and-influencing-factors-of-alic-nac-deep-brain-stimulation-in-treatment-refractory-obsessive-compulsive-disorder-100595368","NCT07031544","Efficacy and Influencing Factors of ALIC-NAc Deep Brain Stimulation in Treatment-Refractory Obsessive-Compulsive Disorder","Efficacy and Influencing Factors of Combined Anterior Limb of Internal Capsule and Nucleus Accumbens Deep Brain Stimulation in Treatment-Refractory Obsessive-Compulsive Disorder","Inclusion Criteria:\n\n* aged 18-65 years old;\n* a diagnosis of OCD based on The Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5);\n* the Y-BOCS total score ≥ 25;\n* met the criteria of treatment refractory. Treatment refractory is defined as failed a) Inadequate response or intolerance to at least three adequate trials of selective serotonin reuptake inhibitors (SSRIs), combined with at least two second-generation antipsychotics as augmentation agents.\n\n  b) Inadequate response or intolerance to cognitive behavioral therapy (CBT) consisting of more than 12 sessions conducted concurrently with adequate dosed SSRIs treatment.\n\nExclusion Criteria:\n\n* Presence of other psychiatric disorders such as organic mental disorders, paranoid personality disorder, or mental retardation.\n* Individuals deemed by the investigator to be at significant risk of suicidal behavior based on clinical assessment.\n* Presence of severe or unstable cardiovascular, respiratory, hepatic, renal, hematologic, endocrine, neurological, or other systemic diseases.\n* History of organic brain disorders, traumatic brain injury, intractable epilepsy, or other neurological conditions.\n* Clinically significant abnormalities in physical examination, laboratory tests, electrocardiogram, or imaging during screening or baseline that, in the investigator's judgment, make the individual unsuitable for the study.\n* History of implantation of a cochlear implant, cardiac pacemaker, cardiac defibrillator, prior unilateral or bilateral implantation of similar devices, or other surgical procedures within the past six months that may affect study participation as judged by the investigator.\n* Contraindications to DBS implantation or deemed unfit for surgery by the investigator.\n* Confirmed HIV-positive status.\n* Pregnant or breastfeeding women, women of childbearing potential with positive blood\u002Furine HCG results at screening, those unable to use effective contraception during the study, or those planning to conceive within three months after study initiation.\n* Participation in another drug or medical device clinical trial currently or within three months prior to screening.\n* Any other condition deemed by the investigator to render the individual unsuitable for the study.",{"count":277,"type":22},[25],"The goal of this clinical trial is to evaluate the efficacy and influencing factors of the combination of the anterior limb of internal capsule and nucleus accumbens (ALIC-NAc) deep brain stimulation (DBS) in patients with treatment-refractory obsessive-compulsive disorder (OCD). The main questions it aims to answer is:\n\nDoes the timing of DBS activation (at 1, 2, or 3 months post-surgery) affect the reduction rate in Y-BOCS scores? Researchers will compare three groups-DBS activated at 1, 2, and 3 months post-surgery-to determine whether earlier or later stimulation leads to greater symptom improvement.\n\nParticipants will:\n\n* Undergo surgical implantation of an intracranial neurostimulation system targeting ALIC-NAc\n* Be randomly assigned to one of three DBS activation timing groups\n* Receive regular clinical assessments over a 6-month follow-up period after activation",[29],[119,333,334,335,336],"deep brain stimulation","anterior limb of internal capsule","nucleus accumbens","activation timing","2025-06-30",{"date":263,"type":41},{"date":340,"type":41},"2024-12-14",{"date":342,"type":22},"2027-03-31",{"name":132,"class":48},10]